Plus Therapeutics (PSTV) News Today $1.09 +0.10 (+10.10%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Plus Therapeutics presented data on ReSPECT-LM Phase 1 trialDecember 18 at 8:08 PM | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 17, 2024 | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital MarketsDecember 11, 2024 | americanbankingnews.comPlus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 4, 2024 | globenewswire.comPlus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope SupplyDecember 3, 2024 | globenewswire.comPlus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trialNovember 27, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Diagnostic Innovations Drive Buy Rating for Plus TherapeuticsNovember 27, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual ConferenceNovember 25, 2024 | globenewswire.comPlus Therapeutics to present FORESEE clinical trial summaryNovember 23, 2024 | markets.businessinsider.comPlus Therapeutics subsidiary to present data on CNSide CSF Assay PlatformNovember 22, 2024 | markets.businessinsider.comPlus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal MetastasesNovember 22, 2024 | globenewswire.comPlus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal MetastasesNovember 21, 2024 | globenewswire.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2024 Earnings Call TranscriptNovember 18, 2024 | msn.comPositive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy RatingNovember 17, 2024 | markets.businessinsider.comPlus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | seekingalpha.comPlus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.dePlus Therapeutics: Promising Growth and Stability Backed by Financial Strength and Clinical InnovationsNovember 15, 2024 | markets.businessinsider.comPlus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...November 15, 2024 | finance.yahoo.comPlus Therapeutics Advances Radiotherapeutics in Q3 2024November 15, 2024 | markets.businessinsider.comPlus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 15, 2024 | markets.businessinsider.comPlus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comA Peek at Plus Therapeutics's Future EarningsNovember 13, 2024 | benzinga.comPlus Therapeutics, SpectronRx announce manufacturing partnershipNovember 6, 2024 | markets.businessinsider.comPlus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing PartnershipNovember 6, 2024 | globenewswire.comPlus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024November 5, 2024 | globenewswire.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, TexasOctober 29, 2024 | globenewswire.comPlus Therapeutics reports progress in brain cancer trialOctober 3, 2024 | uk.investing.comPlus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual MeetingOctober 1, 2024 | globenewswire.comDow Tumbles Over 200 Points; Carnival Posts Upbeat EarningsSeptember 30, 2024 | benzinga.comPlus Therapeutics (NASDAQ:PSTV) Stock, Short Interest ReportSeptember 29, 2024 | benzinga.comPlus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual MeetingSeptember 18, 2024 | globenewswire.comPlus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comBuy Rating Affirmed for Plus Therapeutics Amid Strong Clinical Results and Positive Financial OutlookAugust 20, 2024 | markets.businessinsider.comPlus Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsAugust 17, 2024 | finance.yahoo.comBuy Rating Affirmed for Plus Therapeutics Amidst Promising Clinical Trial ResultsAugust 15, 2024 | markets.businessinsider.comQ2 2024 Plus Therapeutics Inc Earnings CallAugust 15, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comPlus Therapeutics reports progress in CNS cancer trialAugust 14, 2024 | uk.investing.comPlus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 14, 2024 | globenewswire.comPlus Therapeutics earnings: here's what Wall Street expectsAugust 14, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases ConferenceAugust 14, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases ConferenceAugust 13, 2024 | globenewswire.comPlus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases ConferenceAugust 12, 2024 | globenewswire.comPlus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024August 8, 2024 | globenewswire.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 25, 2024 | markets.businessinsider.comPlus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO ConferenceJuly 25, 2024 | globenewswire.comPlus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of CancerJuly 2, 2024 | globenewswire.comPlus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRITJune 7, 2024 | globenewswire.comPlus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement GrantsMay 18, 2024 | finanznachrichten.dePlus Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.com Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday! Just head over here! PSTV Media Mentions By Week PSTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼-0.840.60▲Average Medical News Sentiment PSTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼21▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Femasys News Today Co-Diagnostics News Today DarioHealth News Today Vivos Therapeutics News Today Allurion Technologies News Today NeurAxis News Today Microbot Medical News Today Nephros News Today Innovative Eyewear News Today ReWalk Robotics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
